CHP Merger Corp

CHP Merger — SPAC Merger (March 2022)

45 slides from CHP Merger's SPAC merger presentation, Mar 11, 2022

  1. Slide 1: Investor Presentation March 2022

    Exhibit 99.1 INVESTOR PRESENTATION March 2022 Accelerating MIS Spine Culture | Technology | Accessibility

  2. Slide 2: Disclaimer and Confidentiality Notice

    DISCLAIMER AND CONFIDENTIALITY NOTICE In this presentation, “Accelus”, the “Company”, “we”, “us” and “our” mean Integrity Implants Inc. d/b/a Accelus. All amounts are in U.S. dollars unless otherwise indicated. The information contained herein does not purport to contain all of the information about

  3. Slide 3: Disclaimer and Confidentiality Notice

    DISCLAIMER AND CONFIDENTIALITY NOTICE This presentation includes certain financial measures not presented in accordance with GAAP. These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and asses

  4. Slide 4: Investment Rationale

    INVESTMENT RATIONALE Accelus provides a compelling opportunity for CHP Massive Market Positive Clinical Affordable, Opportunity Outcomes Accessible Solution Attractive Growth Profile, Leverage CHP’s Health High Gross Margins System Relationships Differentiated Platform Disrupting Minimally Invasive

  5. Slide 5: Our Mission: Accelerating Minimally Invasive Spine Surgery

    OUR MISSION: Accelerating Minimally Invasive Spine Surgery ©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 5

  6. Slide 6: Accelus at a Glance

    ACCELUS AT A GLANCE Improving procedures and outcomes, creating favorable economics, and providing broad accessibility Transformational robotic solution, reducing procedural complexity and Clinically-impactful, data- Attractive busines accelerating growth driven, cost-effective, model with pull-thro

  7. Slide 7: Transformational Enabling Technologies

    TRANSFORMATIONAL ENABLING TECHNOLOGIES Robust Portfolio Designed to Enable MIS Spine Surgery Innovative Line of MIS Enabling Spinal Implants Elegant and Affordable Robotic System Multidirectional Expandable Interbody Implant Systems Transformational Robotic Targeting and Navigation Platform * 2-D Fl

  8. Slide 8: Significant Market Opportunity

    SIGNIFICANT MARKET OPPORTUNITY Large Spine Market, Opportunities for Disruption Spinal Fusion Market Overview Size of Accelus’ Current Addressable Market • Large, established U.S. addressable market of $5.3 billion Pedicle Biologics • Demographics support continued market growth Screws and • Interna

  9. Slide 9: Spinal Fusion Surgery Status Quo

    SPINAL FUSION SURGERY STATUS QUO Opportunities to Address Substantial Unmet Clinical Needs MIS Procedures Remain Underpenetrated The Need for Surgical Robotics in Spine MIS techniques offer advantages over open surgical Robotic systems are becoming more widely adopted, procedures for patients, surge

  10. Slide 10: Accelus Offers Key Enabling Technologies

    ACCELUS OFFERS KEY ENABLING TECHNOLOGIES Addressing the Unmet Clinical Needs of Spine Surgery Multidirectional Expandable Interbody Platform Enabling Robotic Targeting and Navigation System Simple Compact Minimal Insertion Profile Affordable Improved Graft Delivery Significant Fusion Rates Providing

  11. Slide 11: Addressing the Constraints of Minimally Invasive Spine Procedures

    ADDRESSING THE CONSTRAINTS OF MINIMALLY INVASIVE SPINE PROCEDURES Simpler, safer procedures with more consistent outcomes • Reduce procedural complexity… Access Without Compromise Adaptive Geometry + Precision Robotics • Expand visualization… • Increase reproducibility… • Reduce radiation… • Address

  12. Slide 12: Accelus Offers a Total MIS Implant Solution

    ACCELUS OFFERS A TOTAL MIS IMPLANT SOLUTION Solutions to address the complete procedure Innovative Expandable Proprietary Biomaterial Robotic Targeting Interbody Platform Fixation Systems Offerings and Navigation ** * Proprietary screw Allograft comprised Economically attractive robotic Differentiat

  13. Slide 13: Product Portfolio

    A Accelus PRODUCT PORTFOLIO

  14. Slide 14: Revolutionary Multidirectional Expandable Implant Technology

    REVOLUTIONARY MULTIDIRECTIONAL EXPANDABLE IMPLANT TECHNOLOGY TM in Action What is “Adaptive Geometry”? Next-generation solution for MIS procedures Proprietary expandable cage technology, featuring multidirectional expansion of interbody devices Why Does it Matter? Minimal insertion profile with maxi

  15. Slide 15: Game-Changing Portfolio of Spinal Implants with Adaptive Geometry

    GAME-CHANGING PORTFOLIO OF SPINAL IMPLANTS WITH ADAPTIVE GEOMETRY Our Mission Solve the clinical challenges of MIS procedures through innovation and enabling technology The Problem MIS solutions have focused on surgical techniques improve footprint, but results are mixed and complications remain Ner

  16. Slide 16: FlareHawk Family of Spinal Fusion Cages

    Broad service offering to address MIS needs FlareHawk Family of Spinal Fusion Cages Designed For: Minimal Insertion Profile Multiplanar Expansion Improved Graft Delivery Minimizing neural retraction Wide footprint with no compromise Open architecture for continuous graft delivery ** Titanium Coated

  17. Slide 17: Pedicle Screw System: Allows Procedure Cross-Sale

    PEDICLE SCREW SYSTEM: ALLOWS PROCEDURE CROSS-SALE * Telescopic Screw Technology Open Proprietary screw technology designed to reduce current Robust implants and frustrations and complications with posterior fixation. instrumentation to Complements robotics platforms. address complex pathology MIS An

  18. Slide 18: Transformational Robotic Targeting and Navigation System

    Optimized for daily use, with a small 30” x 30” footprint Easier to use than alternative robotic and navigation system One-third to one-fourth of the cost of alternative systems TRANSFORMATIONAL ROBOTIC TARGETING AND NAVIGATION SYSTEM ©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBU

  19. Slide 19: Robotic Targeting and Navigation System

    ROBOTIC TARGETING AND NAVIGATION SYSTEM The Problem: Surgeons that need robotics are in facilities that can’t afford them Our Solution: Cost-Effective Without Attractive Surgeon Economics Rapid system positioning with quick and easy Compromise set-up and breakdown allowing surgeons to Precision navi

  20. Slide 20: Robotic, Enabled, Minimally Invasive Targeting and Navigation System

    ROBOTIC, ENABLED, MINIMALLY INVASIVE TARGETING AND NAVIGATION SYSTEM EXTRAORDINARY FEATURES… SMALLER TABLE MOUNTED SYSTEM WITH A NEARFIELD CAMERA FASTER ~35% REDUCTION IN PROCEDURE TIME COMPARED TO THE COMPETITION* MORE AFFORDABLE PRICED AT A FRACTION OF THE COST COMPARED TO THE COMPETITION …WITHOUT

  21. Slide 21: Protected Innovation, Published Clinical Data, Product Pipeline

    PROTECTED INNOVATION ROBUST PORTFOLIO PUBLISHED GLOBAL WITH INNOVATIVE CLINICAL DATA PATENT PRODUCT PIPELINE PROTECTION PEER REVIEWED, MULTI- 510(k) Pathway: 3 CENTER STUDIES ON US PATENTS FlareHawk9 FLAREHAWK 26 LineSider US APPS FlareHawk7 26 PEER REVIEWED ROBOTIC NAVIGATION 1 TiHawk STUDY INT’L P

  22. Slide 22: Peer-Reviewed Clinical Data

    PEER-REVIEWED CLINICAL DATA FlareHawk Clinical Studies Compendium of Published Peer- Reviewed FlareHawk Data • Published in International Journal of Spine Surgery (IJSS) • Three retrospective, peer-reviewed studies • Fusion rates commensurate with PLIF and TLIF procedures, minimal complications Navi

  23. Slide 23: Product Pipeline & ASC Opportunity

    PRODUCT PIPELINE & ASC OPPORTUNITY

  24. Slide 24: Journey of Innovation

    JOURNEY OF INNOVATION Established History of Development With Robust Product Pipeline * * Zform Acquired technology 20 20 15 13 2016 2018 2019 2021 2022 & Beyond 2020 * 2-D * Toro-L Toro-Posterior & Toro-ALIF Toro-Hyperlorotic *FDA clearance pending or pipeline product under development ©2022 ACCELU

  25. Slide 25: Accelus' Next Adaptive Geometry Offering

    ACCELUS’ NEXT ADAPTIVE GEOMETRY OFFERING TM ©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 25

  26. Slide 26: Expandable Platform: Adaptive Geometry Reimagined

    EXPANDABLE PLATFORM Adaptive Geometry Reimagined Expands wide first under minimal load then lifts with wide footprint FACILITATES ENTRANCE INTO LATERAL AND ANTERIOR MARKETS Lateral (LLIF) Posterior (PLIF / TLIF) Anterior (ALIF) 2022 2023 2023 Key Features and Benefits of Toro Platform Infinitely Ins

  27. Slide 27: Ambulatory Surgery Center (ASC) Market

    AMBULATORY SURGERY CENTER (ASC) MARKET ENABLING TECHNOLOGIES DRIVING ASC ADOPTION GROWING ASC OPPORTUNITY • Spine procedures increasingly Enables Outpatient MIS Procedures Solves Complicated moving to ambulatory surgery Issues Simply centers • 86% of spine surgeons expect to use ASCs* • Spine surger

  28. Slide 28: Growth and Financials

    A Accelus GROWTH AND FINANCIALS

  29. Slide 29: Growth Opportunities

    GROWTH OPPORTUNITIES International Expansion Accelerate Grow in targeted Adoption in ASCs international markets Expand Sales Reduce barriers to moving Force Regionally fusion procedures to ASCs Launch New Rapidly expand sales Product Lines Drive Pull- team to capture share Through Revenue Targeting

  30. Slide 30: Financial Highlights

    FINANCIAL HIGHLIGHTS Revenue Forecast 2021E $27.5 5-year Growth REVENUE MILLION Expectations* 2023E $81.0 REVENUE MILLION $176M GROWING AT 2020 to 2025 $125M FORECASTED 60% CAGR $81M $48M $28M $17M Historical Non-GAAP GROSS MARGIN** 80%+ 2020 2021E 2022E 2023E 2024E 2025E *Revenue projections rounde

  31. Slide 31: Investment Takeaways

    INVESTMENT TAKEAWAYS Enabling technologies disrupting minimally invasive spine surgery Vast underserved market with opportunities to capture share Demonstrated value proposition with compelling clinical data Accelerating Robust product pipeline addressing a broader market opportunity Minimally Invas

  32. Slide 32: Appendix I: Financial Detail

    APPENDIX I: FINANCIAL DETAIL

  33. Slide 33: Transaction Overview

    TRANSACTION OVERVIEW Source of Funds Use of Funds Accelus Rollover Equity $413.5 Accelus Rollover Equity $413.5 1 Convertible Note / Series D Investments 6. 2 Cash to Balance Sheet 155.3 Proceeds from Trust Account 187. 1 Extension Premium Payments 3.1 Total Sources $606.8 Estimated Transaction Cost

  34. Slide 34: Compelling Valuation

    COMPELLING VALUATION EV / Revenue EV / Revenue Revenue CAGR 2022E 2023E ’21 – ’23 High Growth 11.9x 9.2x 37% Med-Tech Premium Spine 7.3x 6.0x 21% & Orthopedics Enabling Robotic 14.7x 10.3x 46% Technology 10.5x 6.2x 72% Accelus = $1.6 billion = $1.6 billion = $1.1 billion Precedent Robotic Transactio

  35. Slide 35: High Visibility to 2023 Revenue Growth

    HIGH VISIBILITY TO 2023 REVENUE GROWTH Commentary $81.0 • Sales of existing products lines are Core Product Growth A anticipated to be the largest contributor to • Comprised of our existing lines including: growth, largely driven by pull-through sales • FlareHawk / TiHawk* • LineSider Fixation (pedi

  36. Slide 36: Results of Operations

    RESULTS OF OPERATIONS Year Ended Year-to-Date December 31, September 30, ($ in thousands) 2019 2020 2020 2021 Net Revenue $16,642 $16,871 $11,773 $17,901 Cost of Revenue 3,013 4,479 3,269 4,338 Gross Profit 13,629 12,392 8,504 13,563 Non-GAAP Gross Profit 13,849 13,689 9,519 14,399 Non-GAAP Gross Ma

  37. Slide 37: Non-GAAP Financial Measures

    NON-GAAP FINANCIAL MEASURES Year Ended Year-to-Date December 31, September 30, ($ in thousands) 2019 2020 2020 2021 Net Loss, as reported ($9,771) ($12,416) ($9,196) ($16,295) Adjustments: Add: Interest expense, net 332 288 215 3,737 Add: Amortization of intangible assets 707 707 530 1,079 Add: Depr

  38. Slide 38: Appendix II: Commercial Strategy

    APPENDIX II: COMMERCIAL STRATEGY

  39. Slide 39: Attractive Business Model

    ATTRACTIVE BUSINESS MODEL Enabling technology drives product pull-through Robot Placement Economically attractive option, enabling more surgeons to perform more procedures Pull-Through Screws Procedure Cross-Sale Closed robotic system Opportunities to capture drives sales of fixation additional elem

  40. Slide 40: Established Commercial Footprint

    ESTABLISHED COMMERCIAL FOOTPRINT Strong Commercial Commercialization Infrastructure Strategy ü Dedicated internal sales force ü Rapidly expand sales team ü Grow direct sales force in ü External distributor network targeted markets ü Growing talent pool ü Continue to build capital Boulder, CO sales i

  41. Slide 41: Lumbar Interbody Market by Approach

    LUMBAR INTERBODY MARKET BY APPROACH Posterior MARKET FOR INTERBODY SPINAL 58% Anterior 23% FUSION DEVICES • Total U.S. Spinal Fusion market is $7.3 billion+ • ~250,000 lumbar spinal fusion procedures utilize interbody devices ~150,000 • Accelus’ proprietary products currently only Total Procedures a

  42. Slide 42: Lumbar Interbody Market by Approach: Robust Pipeline

    LUMBAR INTERBODY MARKET BY APPROACH Posterior ROBUST PIPELINE TO FILL OUT 58% Anterior 23% INTERBODY PORTFOLIO* • Toro expands Accelus’ market opportunity Toro-Lateral Toro-PLIF/TLIF Toro-ALIF ~250,000 Total Procedures Addressed by Pipeline ADDITIONAL OPPORTUNITIES • More than 350,000 Cervical Fusio

  43. Slide 43: Appendix III: Leadership Team

    APPENDIX III: LEADERSHIP TEAM

  44. Slide 44: World-Class Spine Leadership

    WORLD-CLASS SPINE LEADERSHIP CHRIS WALSH ALEX LUKIANOV KEVIN WILLIAMSON CEO & Co-Founder Chairman CFO ANDREW WOLF WYATT GEIST CSO CIO BRAD CLAYTON BLAKE STONE KEVIN McGANN CTO General Counsel President ©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE. 44

  45. Slide 45: Chairman of CHP Merger Corp

    CHAIRMAN OF CHP MERGER CORP With an extensive 40+ year background as an Executive and Board member in both “ the health system provider and payor world, I uniquely understand the challenges that face the industry and the technologies with the strong potential to solve them. As such, I look forward t

CHP Merger — SPAC Merger (March 2022) on 6ix